

1 **Pushing beyond specifications: Evaluation of linearity and clinical performance**
2 **of a fully automated SARS-CoV-2 RT-PCR assay for reliable quantification in**
3 **blood and other materials outside recommendations**

4

5 Dominik Nörz¹, André Frontzek², Ulrich Eigner³, Lisa Oestereich^{4,5}, Nicole Fischer¹, Martin
6 Aepfelbacher¹, Susanne Pfefferle^{1*} and Marc Lütgehetmann^{1,5*}

7 ¹ University Medical Center Hamburg-Eppendorf (UKE), Institute of Medical Microbiology, Virology
8 and Hygiene, Hamburg, Germany

9 ² Labor Stein, Mönchengladbach, Germany

10 ³ Labor Limbach, Heidelberg, Germany

11 ⁴ Bernhard Nocht Institute, Leibniz Institute for Tropical Medicine, Hamburg, Germany

12 ⁵ German Center for Infection Research, Partner Site Hamburg-Borstel-Lübeck-Riems, Germany

13 * Equal contribution

14 **Highlights:**

- 15 • Effective reduction of SARS-CoV-2 infectivity by chemical inactivation without affecting assay
16 performance.
- 17 • SARS-CoV-2 IVD for the cobas 6800/8800 is linear over up to seven log steps in different
18 materials including human plasma.
- 19 • Minimal variance of CT values between testing sites indicates high comparability of
20 quantification results.

21

22 **Address correspondence to:**

23 Marc Lütgehetmann

24 Institute of Medical Microbiology, Virology and Hygiene

25 Martinstraße 52

26 D-20246 Hamburg

27 mluetgeh@uke.de

28

29

30 1 Abstract

31 **Background:** The ongoing SARS-CoV-2 pandemic presents a unique challenge to diagnostic
32 laboratories. There are preliminary studies correlating qRT-PCR results from different materials to
33 clinical outcomes, yet, comparability is limited due to the plethora of different assays used for
34 diagnostics. In this study we evaluate clinical performance and linear range for the SARS-CoV-2 IVD
35 (cobas6800/8800 system, a fully automated sample-to-result platform) in different clinically relevant
36 matrix materials outside official specifications. **Methods:** Assay performance was assessed in human
37 plasma, BAL/BL and transport medium following chemical inactivation. For analytical evaluation,
38 respective matrix materials were spiked with SARS-CoV-2 RNA in ten-fold dilution series. The efficacy
39 of chemical inactivation by guanidine hydrochloride solution was confirmed in cell culture infectivity
40 experiments. For correlation, a total of 235 predetermined clinical samples including respiratory
41 swabs, plasma and BAL/BL were subjected to the SARS-CoV-2 IVD test and results were compared.
42 **Results:** The SARS-CoV-2 IVD showed excellent linearity over five to seven log steps depending on
43 matrix material. Chemical inactivation resulted in a reduction in plaque forming units of at least 3.5 log
44 steps, while having no significant impact on assay performance. Inter-run consistency from three
45 different testing sites demonstrated excellent comparability of RT-PCR results (maximum deviation
46 was 1.53 CT). Clinical evaluation for respiratory swabs showed very good agreement with the
47 comparator assay (Positive agreement 95.7%, negative agreement 98.9%). **Conclusion:** The SARS-CoV-
48 2 IVD test for the cobas6800/8800 systems offers excellent linear range and inter-run consistency for
49 quantification of SARS-CoV-2 RNA in different matrices outside official specifications.

50

51 **2 Introduction:**

52 The novel coronavirus SARS-CoV-2 has been subject of extensive study since its emergence in
53 late December 2019 (1, 2). Diagnostic RT-PCR was quickly determined as the gold standard for
54 detecting the new pathogen in patients, in large parts due to the rapid dissemination of
55 complete virus sequences from the assumed origin of the outbreak in China and consecutive
56 publication of specific PCR assays (3, 4). Besides merely confirming the diagnosis, there exists
57 evidence for a correlation between viral loads and clinical outcomes for various respiratory
58 viruses, including Influenza and the original SARS-CoV (5, 6). In the case of SARS-CoV-2 there
59 has already been a flurry of publications describing viral load dynamics in different clinical
60 specimens (7, 8). It can be assumed that this topic will further grow in relevance in the coming
61 months.

62 Reliable quantification of RT-PCR signals is highly dependent on assay specifications and
63 reference materials (9). In the absence of an international standard to serve as reference,
64 quantification of SARS-CoV-2 RNA is ultimately based on a variety of different methods and
65 standards used in the individual labs (8, 10), resulting in inherently poor comparability and
66 reproducibility between testing sites. However, the increasing availability of commercial SARS-
67 CoV-2 RT-PCR kits for widely used fully automated systems offers the opportunity to generate
68 highly consistent PCR results which can then be used for quantification.

69 The cobas6800 system is a fully automated sample-to-result high-throughput RT-PCR
70 platform, capable of performing 384 tests in an 8 hour shift and requiring minimal hands-on
71 time (11). Until very recently, laboratory developed tests (LDT) using the open mode (utility
72 channel) had to be employed to use the system for SARS-CoV-2 testing (10). However, Roche
73 has since received “Emergency use authorization” by the FDA for their own SARS-CoV-2 IVD

74 assay and have made the test available commercially (12). This provides a common ground
75 across different testing sites for quantification of RT-PCR data, especially when taking the
76 remarkable inter-run consistency of the instrument into account (13).

77 The aim of this study was to provide clinical evaluation of the new SARS-CoV-2 IVD assay by
78 Roche and further validate clinical specimen types outside specifications for use in clinical
79 studies. In this context, efficiency and linear range was to be determined in different clinical
80 materials. Lastly, comparability of results was to be evaluated using a multicenter approach
81 for inter-run variability.

82

83 **3 Materials and Methods**

84 ***3.1 Cell culture and virus quantification***

85 Vero cells (ATCC CCL 81) were propagated in DMEM containing 10 % FCS, 1% Penicillin/
86 Streptomycin, 1 % L-Glutamine, (200 mM), 1 % Sodium pyruvate and 1 % non-essential amino
87 acids (all Gibco/ Thermo Fisher, Waltham, USA). A SARS-CoV-2 isolate was rescued from an
88 oropharyngeal swab as described previously (Pfefferle et al., manuscript submitted). For virus
89 quantification, plaque-assays were performed as follows: A tenfold serial dilution series of the
90 virus containing solution was incubated on Vero cells seeded in 24-well plates (500 µl per
91 well). After adsorption at 37°C for 1h, cells were washed once with PBS and overlaid with
92 DMEM containing 1% methylcellulose to prevent virus spreading within the supernatant. After
93 5 days of incubation at 37°C, cells were fixed in 4% formaldehyde (30 min at room

94 temperature), washed once with H₂O and stained with crystal violet solution. Virus titers in
95 initial (stock) solutions were assessed by counting plaques.

96

97 **3.2 Assessment of the virus inactivation capability of 40%** 98 **guanidine hydrochloride**

99 In order to determine the virus inactivation capability of the Roche PCR Media Kit (\leq 40%
100 guanidine hydrochloride in Tris-HCl), 100 μ l of the SARS-CoV-2 stock solution (with an
101 estimated 3×10^7 PFU/ml) were diluted 1:10 in either UTM or E-swab medium (modified Amies
102 medium in Tris-HCl). 500 μ l of each dilution were supplemented 1:1 with Roche PCR-Media,
103 the remaining 500 μ l were supplemented 1:1 with either UTM or E-swab medium. After 30 min
104 of incubation at room temperature, ten-fold serial dilution series of each mixture were used
105 for plaque assays as described above.

106

107 **3.3 Cobas6800 SARS-CoV-2 IVD Test setup**

108 The SARS-CoV-2 IVD dual-target test for the cobas6800/8800 system was obtained from Roche
109 and used according to instructions issued by the manufacturer. Target-1 (RdRp gene) and
110 Target-2 (E gene) properties were analysed separately, though the entire assay was deemed
111 positive as long as one Target returned a positive result. Apart from loading the ready-to-use
112 SARS-CoV-2 IVD-test cartridges onto the device, there are no manual steps required in the
113 assay setup.

114 **3.4 Assessing linearity in different materials**

115 For determining linear range in different matrix materials, an initial 1:20 dilution of cell culture
116 supernatant containing SARS-CoV-2 (isolate HH-1) was prepared using normal human plasma
117 (SARS-CoV-2 RNA negative) as diluent. For BAL/BL, clinical specimens previously tested PCR-
118 negative for SARS-CoV-2 were pooled to serve as matrix material. The initial stock was used
119 to generate tenfold dilution series, which were subjected to the SARS-CoV-2 IVD test in 8
120 repeats for each step.

121

122 **3.5 Comparing clinical samples**

123 All tested clinical samples were predetermined positive or negative in routine diagnostics
124 using the SARS-CoV-2 UCT (utility channel test) on the cobas6800 system (10). Oropharyngeal
125 swabs or nasopharyngeal swabs were collected using eSwab collection kits (Copan, Italy). All
126 samples were pre-treated by adding 1:1 “cobas PCR media” (Roche, $\leq 40\%$ guanidine
127 hydrochloride in Tris-HCL buffer) for safe handling. To obtain EDTA-plasma, EDTA-blood
128 samples were separated by centrifugation and transferred into fresh sample tubes.

129 A total of 180 respiratory swab samples, 43 positive plasma samples and 12 positive BAL/BL
130 samples were retrieved from storage at -20°C (< 1 month) and subjected to the SARS-CoV-2
131 IVD test. CT values of Target-1 (RdRp gene) and Target-2 (E gene) were compared to the prior
132 result of the comparator assay (targeting the viral E gene).

133 This work was conducted in accordance with §12 of the Hamburg hospital law (§12 HmbKHG).

134 The use of anonymized samples was approved by the ethics committee, Freie und Hansestadt

135 Hamburg, PV5626.

136

137 ***3.6 Inter-run variability and comparability of results***

138 Inter-run variability was compared between a total of four different instruments, located at 3

139 different testing sites. Triplicates of a solution containing diluted SARS-CoV-2 infected cell

140 culture supernatant were prepared as described above. Concentrations of SARS-CoV-2 RNA

141 were estimated to be within linear range of the assay. Spiked sample sets were sent to “Labor

142 Limbach”, Heidelberg and “Labor Stein”, Moenchengladbach for analysis with the SARS-CoV-

143 2 IVD test using their own cobas6800 instruments. Ct values were reported and compared.

144 The total number of measurements for each series was 11.

145

146 **4 Results**

147 ***4.1 Supplementing swab medium with guanidine hydrochloride***

148 ***solution results in significant reduction of plaque formation***

149 To confirm effective neutralization of infectious virus in clinical specimens, cell culture

150 supernatants containing high concentrations of SARS-CoV-2 (HH-1) were initially diluted (1:20)

151 in UTM and eSwab medium, with and without adding 1:1 with Roche cobas PCR media ($\leq 40\%$

152 guanidine hydrochloride in Tris-HCL buffer) to the mix. Stocks treated with guanidine
153 hydrochloride solution showed a reduction in plaque forming units of at least 3.5 log steps
154 compared to control (*figure 1*). No significant differences were observed when comparing PCR
155 efficiency in UTM to UTM or eSwab medium supplemented with guanidine hydrochloride
156 solution (*figure 2, Supplement 1*).

157

158 **4.2 Linear range for different matrix materials using cell culture** 159 **stocks**

160 Linear range of the assay was assessed in a variety of matrices, including swab medium with
161 and without chemical inactivation, human plasma and BAL/BL. Both Targets exhibited slopes
162 in the range of 3 to 3.3 CT in all tested materials except plasma, indicating very good efficiency
163 (*figure 2, supplement 1*). Slopes were markedly higher in plasma, approximately 4 CT for both
164 Targets. The same behavior was observed with the SARS-CoV-2 UCT (*Supplement 2*).
165 Both assays demonstrated excellent linearity over a range of 5 - 7 log steps (7 log in UTM incl.
166 guanidine hydrochloride, 6 log in plasma, 5 log in BAL/BL), with the Target-2 assay performing
167 slightly better and being highly linear up to a CT of 35.

168

169 **4.3 SARS-CoV-2 IVD results in clinical samples within linear range** 170 **show excellent correlation with the comparator assay**

171 For clinical validation, a set of predetermined samples was subjected to testing with the SARS-
172 CoV-2 IVD and results were compared to the comparator assay. The SARS-CoV-2 IVD result

173 was reported as “positive” as long as one of the two Targets returned a positive result. A total
174 of 180 respiratory swabs (predetermined positive: 93; predetermined negative: 87) tested
175 with the assay resulted in robust positive and negative agreement of 95.7 % and 98.9 %
176 respectively (*figure 3a, table 1*).

177

		UCT	
		Positive	Negative
SARS-CoV-2 IVD	Positive	89	1
	Negative	4	86
<u>Total number:</u>		180	

178 *Table 1: Clinical evaluation of the SARS-CoV-2 IVD assay for 180 predetermined respiratory*
179 *swab samples. UCT: Utility Channel Test (comparator assay)*

180

181 All discrepant positive (n = 1) and negative samples (n = 4) were at high CT values (> CT 30),
182 indicating very low concentrations of viral RNA. Concerning CT values, Target-2 (E gene)
183 showed the highest consistency with the reference assay, which is also targeting the viral E
184 gene.

185 43 predetermined positive plasma samples were correctly identified by the SARS-CoV-2 IVD,
186 though Target-1 failed to detect viral RNA in a number of samples containing only low
187 concentrations (*figure 3b*). For both human plasma and BAL/BL (n = 12, *figure 3c*), results
188 correlated very well with the comparator assay within linear range.

189

190 **4.4 Inter-run variability between different machines and testing** 191 **sites**

192 A set of samples spiked with SARS-CoV-2 RNA (HH-1) was subjected to testing on a total of
193 four different instruments at three different testing sites. Deviations of CT values did not
194 exceed 1.53 CT in UTM and 0.53 CT in human plasma, indicating excellent comparability of
195 results both between devices and testing sites (*Figure 4*).

196

197

198 **5 Discussion**

199 The recently released SARS-CoV-2 IVD for the cobas6800/8800 systems made automated
200 high-throughput testing available to a wider range of diagnostic facilities. First studies
201 providing clinical evaluation have demonstrated good agreement with established reference
202 assays (12). The benefits of automation for molecular diagnostics have been discussed
203 extensively in previous studies (11, 14). While a variety of devices offering sample-to-result
204 solutions could already be employed for SARS-CoV-2 testing during the early weeks of the
205 outbreak (including but not limited to the cobas6800 (10), Panther fusion (15) and NeuMoDx
206 96 (16)), they did require utilization of the systems open modes and the use of lab developed
207 tests (LDT), thus limiting their viability for widespread implementation. The SARS-CoV-2 IVD,
208 however, is a lot more accessible and instruments are relatively widely available in diagnostic
209 labs, thus providing a well standardized common ground for comparable quantification results
210 and viral load monitoring. At present, the assay is limited by relatively narrow
211 recommendations for matrix materials and lack of robust data on analytical and clinical

212 performance. The aim of this study was to go beyond specifications and validate the assay on
213 relevant clinical materials such as BAL/BL and blood, as well as evaluating the efficacy and
214 performance impact of chemical inactivation procedures.

215 Safety has been a serious concern when handling clinical samples potentially containing SARS-
216 CoV-2 in diagnostic laboratories. While Bio Safety Level 3 (BSL3) conditions are required for
217 procedures that actively enrich or propagate infectious virus (i.e. cell culture), diagnostic
218 samples are usually processed under BSL2 cabinets. Heat inactivation protocols are
219 widespread in some parts of the world as there exists some evidence for their efficacy with
220 SARS-CoV and MERS-CoV (17, 18), however, there are also reports claiming that these
221 procedures may lead to false negative PCR results (19). Pastorino et al. showed that exposure
222 to temperatures as high as 92°C is necessary to completely abolish infectivity, also resulting in
223 substantial degradation of viral RNA in samples (20). Here we show that pre-treating samples
224 by adding 1:1 guanidine hydrochloride solution (cobas PCR Media) reduces plaque formation
225 by at least 3.5 log steps. This procedure did not have significant impact on assay performance
226 in UTM (or eSwab medium). However, guanidine hydrochloride solution alone may not be
227 sufficient to completely inactivate all infectious virus in samples (20, 21).

228 Since the beginning of the outbreak, some clinical studies have reported on quantitative and
229 semi-quantitative detection of SARS-CoV-2 RNA in different clinical materials over the course
230 of treatment (7, 8, 22). However, quantification results that are precise and reproducible
231 across laboratories require highly standardized reference material, which is not yet available.
232 Vogels et al. recently provided data on performance and linearity for the most commonly used
233 SARS-CoV-2 inhouse assays, demonstrating that linear range and PCR efficiency does vary to
234 a considerable degree (23). Notably, the Sarbeco-E assay by the Charité Berlin (3) and ORF1ab

235 assay by the Hong-Kong University (24) seem to stand out from the crowd, featuring both a
236 maximum of analytical sensitivity and wide linear range. However, other factors such as
237 extraction methods, and choice of enzymes and cyclers will render comparability between
238 sites difficult, even when using the same assays.

239 In this study we demonstrate that the SARS-CoV-2 IVD dual-target assay is highly efficient and
240 offers a wide linear range in different types of matrix materials outside official specifications.
241 Based on our data, it seems preferable to use the Target-2 (E gene) CT for quantification
242 purposes as it performed slightly better than Target-1 (RdRp gene) in this trial. Compared to
243 the inhouse assay SARS-CoV-2 UCT, the SARS-CoV-2 IVD assay showed good agreement for a
244 total of 180 respiratory swab samples, which is in line with previously reported data (12).
245 Furthermore, good correlation was observed for 43 positive plasma and 12 positive BAL/BL
246 samples within linear range of the IVD assay.

247 Fully automated RT-PCR systems performing nucleic acid extraction, PCR and signal analysis,
248 provide a standardized common ground between testing sites. In order to evaluate to what
249 degree results are comparable between different instruments, predetermined identical sets
250 of 7 samples were subjected to testing on four different devices at three different testing sites
251 in Germany (UKE in Hamburg, "Labor Limbach" in Heidelberg and "Labor Stein" in
252 Moenchengladbach). There was only minimal variance in CT values for human plasma samples
253 (range dCT: 0.53) and slightly higher in UTM samples (range dCT: 1.53). This further underpins
254 the reproducibility of results obtained from the SARS-CoV-2 IVD which may prove very useful
255 in the context of viral-load monitoring and in clinical multicentre studies.

256

257 **6 Conclusion**

258 In this study we provide evaluation for different matrix materials and clinical performance of
259 the SARS-CoV-2 IVD for the cobas6800/8800 systems. We observed excellent linearity over
260 five to seven log steps in different clinically relevant materials outside assay specifications,
261 including human plasma samples, BAL/BL and swab medium pre-treated for chemical
262 inactivation. Furthermore, deviations in CT values were minimal when identical samples were
263 analyzed at different testing sites. The assay showed excellent correlation with the
264 comparator assay for all specimen types analyzed, indicating compatibility of a variety of
265 clinical materials despite not being officially recommended for use by the manufacturer.
266 Overall, this data demonstrates the viability of the assay for providing reproducible
267 quantification of SARS-CoV-2 RNA in respiratory samples and human plasma for viral load
268 monitoring and clinical studies.

269

270 **7 Author contribution**

271 ML, SP, LO, MA and NF conceptualized and supervised the study. DN, AF and UE performed the
272 experiments. DN, ML and SP wrote the initial draft of the manuscript. All authors agreed to the
273 publication of the final manuscript.

274

275 **8 Competing interest**

276 UE and ML received speaker honoraria and related travel expenses from Roche Diagnostics.

277 Parts of the material used for this study were provided by Roche Molecular Solutions (Pleasanton,
278 USA).

279

280 **References:**

- 281 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
282 Pneumonia in China, 2019. *N Engl J Med*. 2020.
- 283 2. Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel
284 human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.
285 *Emerg Microbes Infect*. 2020;9(1):221-36.
- 286 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel
287 coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25(3).
- 288 4. WHO. Use of laboratory methods for SARS diagnosis. World Health Organisation Website
289 (who.int). 2020.
- 290 5. Hijano DR, Brazelton de Cardenas J, Maron G, Garner CD, Ferrolino JA, Dallas RH, et al. Clinical
291 correlation of influenza and respiratory syncytial virus load measured by digital PCR. *PLoS One*.
292 2019;14(9):e0220908.
- 293 6. Chu CM, Poon LL, Cheng VC, Chan KS, Hung IF, Wong MM, et al. Initial viral load and the
294 outcomes of SARS. *CMAJ*. 2004;171(11):1349-52.
- 295 7. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper
296 Respiratory Specimens of Infected Patients. *N Engl J Med*. 2020.
- 297 8. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics and disease severity in
298 patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective
299 cohort study. *BMJ*. 2020;369:m1443.
- 300 9. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. *Nature*
301 *Protocols*. 2006;1(3):1559-82.
- 302 10. Pfefferle S, Reucher S, Nörz D, Lütgehetmann M. Evaluation of a quantitative RT-PCR assay for
303 the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system.
304 *Eurosurveillance*. 2020;25(9):2000152.
- 305 11. Eigner U, Reucher S, Hefner N, Staffa-Peichl S, Kolb M, Betz U, et al. Clinical evaluation of
306 multiplex RT-PCR assays for the detection of influenza A/B and respiratory syncytial virus using a high
307 throughput system. *J Virol Methods*. 2019;269:49-54.
- 308 12. Poljak M, Korva M, Knap Gašper N, Fujs Komloš K, Sagadin M, Uršič T, et al. Clinical evaluation
309 of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the
310 COVID-19 pandemic. *Journal of Clinical Microbiology*. 2020:JCM.00599-20.
- 311 13. Eigner U, Norz D, Reucher S, Furrer J, Sun J, Chu K, et al. Detection of *C. difficile* toxin as a model
312 assay for performing fully automated high-throughput RT-PCR on clinical stool samples. *J Microbiol*
313 *Methods*. 2020;172:105882.
- 314 14. Greub G, Sahli R, Brouillet R, Jaton K. Ten years of R&D and full automation in molecular
315 diagnosis. *Future Microbiol*. 2016;11(3):403-25.
- 316 15. Cordes AK, Heim A. Rapid random access detection of the novel SARS-coronavirus-2 (SARS-
317 CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion. *J Clin Virol*.
318 2020;125:104305.

- 319 16. Nörz D, Fischer N, Schultze A, Kluge S, Mayer-Runge U, Aepfelbacher M, et al. Clinical
320 evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in
321 the hospital setting. *Journal of Clinical Virology*. 2020:104390.
- 322 17. Leclercq I, Batejat C, Burguiere AM, Manuguerra JC. Heat inactivation of the Middle East
323 respiratory syndrome coronavirus. *Influenza Other Respir Viruses*. 2014;8(5):585-6.
- 324 18. Darnell ME, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus that induces
325 severe acute respiratory syndrome, SARS-CoV. *J Virol Methods*. 2004;121(1):85-91.
- 326 19. Pan Y, Long L, Zhang D, Yan T, Cui S, Yang P, et al. Potential false-negative nucleic acid testing
327 results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation of samples
328 with low viral loads. *Clin Chem*. 2020.
- 329 20. Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel R. Evaluation of heating and chemical
330 protocols for inactivating SARS-CoV-2. *bioRxiv*; 2020.
- 331 21. Smither SJ, Weller SA, Phelps A, Eastaugh L, Ngugi S, O'Brien LM, et al. Buffer AVL Alone Does
332 Not Inactivate Ebola Virus in a Representative Clinical Sample Type. *Journal of clinical microbiology*.
333 2015;53(10):3148-54.
- 334 22. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and
335 transmissibility of COVID-19. *Nat Med*. 2020.
- 336 23. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity and
337 efficiency comparisons of SARS-COV-2 qRT-PCR primer-probe sets. *medRxiv*.
338 2020:2020.03.30.20048108.
- 339 24. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular Diagnosis of a Novel
340 Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia. *Clin Chem*. 2020;66(4):549-55.

341

342

343

344

345 **1 Figure legend**

346 **1.1 Figure 1**

347 Reduction of plaque forming units (PFU) by guanidine hydrochloride solution. A stock solution of cell
348 culture supernatant containing SARS-CoV-2 (HH-1) was diluted 1:20 in UTM or eSwab medium alone
349 or supplemented 1:1 with cobas PCR Media. A 10-fold dilution series was prepared and 200µL added
350 to Vero cells grown to fluency in a 24 well plate.

351 **1.2 Figure 2**

352 Linear range of Target-1 and Target-2 in different matrix materials. A stock solution of cell culture
353 supernatant containing SARS-CoV-2 (HH-1) was used to prepare a 10-fold dilution series within
354 indicated materials. A total of 8 repeats was tested per dilution step. Blue dots: measurements within
355 linear range of Target-2, considered for trendline and correlation. Orange dots: measurements outside
356 linear range, not considered for trendline and correlation. CPM: cobas PCR media ($\leq 40\%$ guanidine
357 hydrochloride in Tris-HCl).

358 **1.3 Figure 3**

359 Clinical evaluation of the SARS-CoV-2 IVD compared to the comparator assay, SARS-CoV-2 UCT (utility
360 channel test). Predetermined clinical samples previously analyzed in routine diagnostics were retrieved
361 from storage at -20°C and subjected to testing with the SARS-CoV-2 IVD. X-axis: UCT CT; Y-axis: IVD CT;
362 ND: "Not Detected"; Blue dots: measurements within linear range of Target-2, considered for trendline
363 and correlation; Orange dots: measurements outside linear range, not considered for trendline and
364 correlation.

365 **1.4 Figure 4**

366 Evaluation of inter-run variability on four different instruments. Sets of seven identical spiked samples
367 were sent to different laboratories in Germany for testing with the SARS-CoV-2 IVD. Material types
368 were as indicated. CT values were reported and compared. UKE-HH1: Instrument No1 at University
369 Medical Center Hamburg-Eppendorf. UKE-HH2: Instrument No2 at University Medical Center
370 Hamburg-Eppendorf. Labor Stein: Moenchengladbach. Labor Limbach: Heidelberg.

371

Figure 1

a)






Figure 2


Target 1: UTM + CPM




Target 1: Plasma




Target 1: BAL/BL



Target 2: UTM + CPM



Target 2: Plasma



Target 2: BAL/BL








Figure 3

a)



b)



c)





Figure 4

Sample Set 1

Sample Set 2

